FDA data links energy drinks to 11x higher heart stoppage risk in young adults

A new review of federal safety data indicates that energy drinks and caffeine supplements are associated with a substantially higher rate of heart stoppages in young adults. The study analyzed reports submitted to the U.S. Food and Drug Administration (FDA) between 2017 and 2025. Researchers found that heart stoppages occurred approximately 11 times more frequently in cases involving caffeine or stimulant products compared to those involving non-caffeinated items.

The analysis covered a total of 28,345 adverse event reports. Within this dataset, 854 reports specifically mentioned energy drinks or dietary supplements containing caffeine or other stimulants. The team compared these cases against 27,491 reports involving products without such ingredients. The data showed that reports including caffeine-based items were about 4.5 times more likely to cite heart attacks. They were also four times more likely to list ventricular arrhythmias or heart palpitations.

Adults aged 18 to 34 accounted for approximately 45 percent of the reports linking caffeine products to cardiovascular events. This demographic is typically not considered at high risk for such conditions. The researchers observed similar patterns among both male and female patients. Sai Samayamanthula of the University of Virginia noted that these products are marketed as daily consumables and sold next to soda and water. This placement leads many consumers to assume they carry no real risk.

Samayamanthula stated that while occasional use may pose a low risk for healthy individuals, habitual consumption can quickly exceed the recommended daily limit for caffeine. The team presented these preliminary findings at an American Heart Association session in Chicago starting November 6. The results are considered provisional until they appear in a peer-reviewed scientific journal. The researchers emphasized that the study shows an association rather than a direct cause.

The study authors called for more systematic oversight of the safety of caffeine and stimulant products. They advised healthcare providers to ask young patients about recent or regular use of these items when symptoms include palpitations, chest pain, or fainting. The findings suggest that current labeling and placement may underestimate the potential for cardiovascular damage in younger, generally healthy populations.